Detalhe da pesquisa
1.
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Clin Immunol
; 176: 87-93, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28108364
2.
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Int J Mol Sci
; 16(9): 21832-45, 2015 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26378517
3.
Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study.
Brain Behav
; 9(7): e01332, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31168964
4.
Tumefactive MS lesions under fingolimod: a case report and literature review.
Neurology
; 81(19): 1654-8, 2013 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24097813
5.
Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
PLoS One
; 7(2): e31784, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22363732
6.
Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options.
Drug Discov Today
; 16(1-2): 8-21, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21055477
7.
Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
J Neuroimmunol
; 234(1-2): 148-54, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21450349